mAbxience Research S.L.
mAbxience Research S.L. is a Spain-based biotechnology company running 2 late-stage cancer trials in melanoma and non-small-cell lung cancer.
Overview
mAbxience Research S.L., based in Madrid, Spain, is a biotechnology company. mAbxience is a vertically integrated biopharmaceutical company that develops biosimilars and operates an independent contract development and manufacturing organisation (CDMO) platform. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3) in melanoma and non-small-cell lung cancer. The largest, NCT06687369 (A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)), plans to enrol 726 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyKrystal Biotech
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyMultitude Therapeutics
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyiOnctura
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyGeorgiamune
Shares Melanoma and the tag ctgov-sponsor.
- CompanyAvistone Biotechnology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyMaia Biotechnology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyShanghai Juncell Therapeutics
Shares Melanoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanySTCube
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.